The present invention is a technology that significantly simplifies the measurement of BAT by PCR-based quantification of exosomal microRNA-92a in serum. Exosomal miR-92a levels inversely correlate with BAT activity. This novel method is as the first of its kind qualified to routinely measure the BAT activity in large cohorts of patients. The measurement of BAT activity is not only important in the diagnosis and treatment of weight-related diseases, but is also a screening tool for the development of drugs that regulate the BAT activity. Such drugs are of use in pathological leanness (e.g. cachexia), obesity and other metabolic diseases. The invention has been validated by studies in mice and man. On behalf of the University of Bonn, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development. In case of interest we will be pleased to inform you about the patent status.
Further information: PDF
Phone: +49 (0)208/94105 10
Dipl.-Ing. Alfred Schillert
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
firstname.lastname@example.org | TechnologieAllianz e.V.
Peltier Adsorption Trap
29.11.2016 | TechnologieAllianz e.V.
Innovative method for producing analytical suspension cell lines
24.11.2016 | TechnologieAllianz e.V.
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy